ExiTide Reviews: Company Publishes Updated 2026 Ingredient Disclosure with 11-Ingredient Formula

Updated product information identifies nine nutritional and botanical ingredients and two probiotic species with per-serving amounts while separating label disclosure from evidence concerning individual ingredients

NEW CITY, New York, September 17, 2026 — Instituto Experience has published updated 2026 product information for ExiTide, providing a complete ingredient and amount breakdown for the dietary supplement’s 11-component formula. The updated disclosure identifies nine nutritional, botanical and fiber-based ingredients by amount and two probiotic organisms by colony-forming units, providing consumers with additional information for evaluating the formulation against published research.

According to the current product information, one ExiTide capsule contains 442 milligrams of nutritional, botanical and fiber ingredients, together with a combined 2 billion CFU of probiotics.

The listed formula includes riboflavin, mangosteen powder, prickly pear extract, cinnamon bark extract, konjac fiber, alpha-lipoic acid, turmeric extract, berberine hydrochloride and resveratrol. The probiotic portion lists Bifidobacterium breve and Akkermansia muciniphila.

The updated information is intended to clarify what is present in the formula rather than establish that ExiTide produces outcomes reported in independent studies involving individual ingredients.

“Ingredient disclosure is most useful when consumers can distinguish what is actually present in a product from what has been studied independently,” said Sarah Andrews, Media Relations at Instituto Experience. “Publishing the amount of each ingredient makes that comparison possible, but an ingredient appearing on a label should not automatically be treated as proof that the finished formula will reproduce results from a separate clinical study.”

ExiTide’s Current Ingredient Disclosure

The current ExiTide product information lists the following amounts per one-capsule serving:

• Riboflavin, or vitamin B2 — 25 mg

• Mangosteen powder — 100 mg

• Prickly pear extract, 4:1 — 100 mg

• Cinnamon bark extract, 10:1 — 100 mg

• Konjac fiber — 50 mg, standardized to 90% glucomannan

• Alpha-lipoic acid — 25 mg

• Turmeric extract — 15 mg, standardized to 95% curcumin

• Berberine HCl — 15 mg

• Resveratrol — 12 mg

• Bifidobacterium breve — 1 billion CFU

• Akkermansia muciniphila — 1 billion CFU

The non-probiotic ingredients total 442 mg per capsule, while the two listed probiotic organisms provide a combined 2 billion CFU.

The updated label information provides considerably more specificity than category descriptions such as “fiber,” “probiotics” or “metabolic nutrients.” At the same time, ingredient disclosure and clinical evidence remain separate questions.

A disclosed amount allows a reader to compare a formula with the amounts and ingredient forms used in published research. It does not establish that the commercial product itself has been clinically tested or that it will produce a particular outcome.

Riboflavin Has an Established Nutritional Role

Riboflavin, also known as vitamin B2, is the largest vitamin component listed in the ExiTide formula at 25 mg per capsule. The National Institutes of Health Office of Dietary Supplements identifies riboflavin as an essential component of the coenzymes flavin mononucleotide and flavin adenine dinucleotide. These coenzymes participate in energy production, cellular function and the metabolism of fats, drugs and steroids.

That established nutritional role should be distinguished from a product-specific weight-management claim. The presence of riboflavin in ExiTide establishes that the formula supplies vitamin B2. It does not establish that ExiTide independently increases weight loss, alters metabolic disease or produces a particular energy-related outcome.

Konjac Fiber Illustrates Why Dose Matters

ExiTide also lists 50 mg of konjac fiber standardized to 90% glucomannan, equivalent to approximately 45 mg of glucomannan based on the stated standardization. Glucomannan is a soluble dietary fiber derived from konjac root. It has been investigated in controlled research concerning satiety, gastrointestinal function and body weight.

However, the National Institutes of Health Office of Dietary Supplements describes the evidence for glucomannan and weight loss as inconsistent.

Clinical studies summarized by NIH have typically used glucomannan in gram-level daily amounts rather than the milligram-level amount listed for ExiTide. Reviews of randomized trials have also reached mixed conclusions about whether glucomannan produces meaningful changes in body weight.

For that reason, findings from trials using substantially different quantities should not be represented as evidence that the amount contained in ExiTide produces the same result. The ingredient’s presence is factual. A specific weight-loss outcome from the finished product would require separate evidence.

Cinnamon Research Also Requires Caution

The ExiTide formula lists 100 mg of cinnamon bark extract at a stated 10:1 concentration.

Cinnamon has been examined in numerous studies involving glucose metabolism and other metabolic measurements. However, research findings have varied according to population, cinnamon species, formulation, dose, study duration and outcome. The National Center for Complementary and Integrative Health states that current research does not clearly support using cinnamon for any health condition and that evidence concerning diabetes and weight loss remains uncertain.

This distinction is particularly relevant to dietary-supplement communications. Research showing an association or measured change for a specific cinnamon preparation should not be rewritten as evidence that a different commercial formula treats diabetes, lowers blood glucose or causes weight loss.

ExiTide should therefore not be characterized as a treatment for diabetes or any other diagnosed metabolic condition based on the presence of cinnamon.

Berberine and Alpha-Lipoic Acid Are Included at Disclosed Amounts

The formula additionally lists 15 mg of berberine hydrochloride and 25 mg of alpha-lipoic acid. Both compounds have been examined in metabolic research, but the existence of research on an ingredient does not establish a clinical effect for every dose or combination in which that ingredient appears.

NCCIH notes that some studies involving berberine have suggested possible effects on blood-sugar-related measurements, while also emphasizing that the body of research has limitations and does not support replacing established medical treatment with a dietary supplement.

Alpha-lipoic acid has likewise been studied in several clinical contexts, including diabetic neuropathy, but the available evidence does not establish that the amount contained in ExiTide treats diabetes or any complication of diabetes. Consumers using prescription medications, particularly medications affecting blood glucose, should discuss supplement use with an appropriate healthcare professional.

Probiotic Evidence Depends on More Than the Species Name

The updated ExiTide information also identifies two probiotic organisms: Bifidobacterium breve and Akkermansia muciniphila, each listed at 1 billion CFU.

The disclosure is more informative than simply stating that the formula contains “probiotics,” but an important research limitation remains. Published probiotic studies frequently evaluate specifically identified strains, preparations and doses rather than every organism belonging to a species.

For example, randomized clinical research has evaluated the specifically identified Bifidobacterium breve B-3 strain in adults. Those findings apply to B-3 under the conditions tested and should not automatically be applied to another B. breve preparation whose strain identity has not been established as the same.

The same caution applies to Akkermansia muciniphila.

Human studies of A. muciniphila have used defined research preparations, including specified live or pasteurized forms, controlled doses and selected participant populations. Recent randomized research has continued to examine the organism in weight-management and metabolic contexts, but those studies do not establish that every A. muciniphila-containing product has equivalent effects.

ExiTide’s current ingredient information identifies the probiotic organisms at the species level but does not, in the product information reviewed for this release, establish that they are the same strain and preparation evaluated in any individual clinical study. Consequently, this release does not attribute strain-specific clinical results to ExiTide.

Botanical Ingredients Provide Additional Formula Context

The remaining botanical ingredients include mangosteen powder, prickly pear extract, turmeric extract and resveratrol. All four ingredients have appeared in nutritional or biomedical research, but studies vary widely in extract type, standardization, amount, study population and measured outcome.

Their inclusion on the ExiTide label therefore provides information about the composition of the product rather than proof of a specific result.

The updated disclosure makes it possible to identify what the product contains and compare those amounts with independently published research. Such comparisons should account for differences in formulation instead of treating the name of an ingredient as sufficient evidence.

Ingredient Research Is Not Finished-Product Evidence

The principal distinction underlying the updated disclosure is the difference between three separate statements: First, an ingredient can have an established nutritional or biological role. Second, an independently conducted study can report a result involving a particular form and amount of that ingredient.

Third, a finished commercial formulation can demonstrate an outcome when the complete product itself is evaluated under controlled conditions.

Those statements are not interchangeable. The research discussed in connection with ExiTide concerns individual nutrients, botanicals, fibers or specifically studied probiotic preparations. It should not be interpreted as a clinical evaluation of the complete ExiTide formula.

This release does not identify a randomized clinical trial demonstrating that the finished ExiTide product causes weight loss, treats metabolic disease or reproduces outcomes obtained with separately studied ingredients.

Positioning Within a Daily Wellness Routine

ExiTide is marketed as a dietary supplement for adults and is intended to be used alongside broader lifestyle practices. Dietary supplements do not replace the established roles of balanced nutrition, appropriate energy intake, physical activity, sleep and medical care in long-term health and weight management.

The presence of several ingredients associated with nutritional or metabolic research does not mean their effects are additive, nor does a larger number of ingredients necessarily produce a greater clinical effect. How ingredients interact within a finished multi-component formulation is a separate research question from how each ingredient behaves when studied individually.

Safety Considerations

Consumers should review the current product label before beginning any dietary supplement. Some supplement ingredients can interact with medications or may be unsuitable for people with particular medical conditions. Botanical extracts and fiber ingredients may also produce gastrointestinal or other adverse effects in some individuals.

People who are pregnant or breastfeeding, taking prescription medications, preparing for surgery, or managing diabetes or another diagnosed medical condition should discuss dietary-supplement use with a qualified healthcare professional. ExiTide is not intended as a substitute for medical evaluation, prescribed medication or treatment of a diagnosed condition.

Find Out More on Exitide Official website.

Frequently Asked Questions

What is new about the 2026 ExiTide product information?

The updated information provides a complete 11-ingredient disclosure with individual milligram amounts for nine nutritional, botanical and fiber ingredients and CFU amounts for two probiotic organisms. This provides more detail than broad ingredient-category descriptions and allows the formula to be compared more accurately with published research.

Does the ingredient research prove that ExiTide causes weight loss?

No. Research on an individual ingredient does not establish that the complete ExiTide formulation causes weight loss. Studies can involve different ingredient forms, concentrations, doses, populations and treatment periods. A product-specific clinical conclusion would require evidence involving the finished formulation itself.

Why does probiotic strain identity matter?

Probiotic effects can depend on the specific strain studied rather than only the species name. A study involving Bifidobacterium breve B-3, for example, does not establish that every B. breve preparation produces the same outcome. ExiTide currently identifies its probiotic organisms as B. breve and A. muciniphila, so strain-specific research should not automatically be attributed to the product unless the relevant strain identity is confirmed.

Does a disclosed ingredient amount guarantee effectiveness?

No. Ingredient disclosure improves transparency but does not guarantee a clinical outcome. The amount, ingredient form, bioavailability, formulation, research population and intended outcome all affect how scientific evidence should be interpreted. Disclosure makes evidence comparison possible; it does not replace product-specific research.

Regulatory Disclosure

ExiTide is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease.

Scientific references concerning riboflavin, glucomannan, cinnamon, berberine, alpha-lipoic acid, probiotics or other ingredients relate to independently conducted research and should not be interpreted as evidence that the finished ExiTide formulation produces the same results.

References to government agencies, universities, researchers or scientific journals do not imply their endorsement of ExiTide, Instituto Experience or any related commercial product.

About Instituto Experience

Instituto Experience Ltda was established in 2020 and is part of the broader Grupo Experience organization. The company operates across digital education, information products and consumer supplement categories. ExiTide is one of the dietary-supplement products associated with its consumer wellness operations.

Media Contact

Sarah Andrews
Media Relations
Instituto Experience
Email: support@exitide.com
Phone: +1 (507) 448-8145

19655 E 35th Drive, Suite 100 Aurora, CO 80011

Official Website

Research Sources

National Institutes of Health, Office of Dietary Supplements — Riboflavin: Fact Sheet for Health Professionals.

National Institutes of Health, Office of Dietary Supplements — Dietary Supplements for Weight Loss: Fact Sheet for Health Professionals.

National Center for Complementary and Integrative Health — Cinnamon: Usefulness and Safety.

National Center for Complementary and Integrative Health — Diabetes and Dietary Supplements: What You Need to Know.

Sung HK, et al. Body Fat Reduction Effect of Bifidobacterium breve B-3: A Randomized, Double-Blind, Placebo Comparative Clinical Trial. Nutrients. 2023.

Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019.

Consumer Notice: Individual responses to dietary supplements vary. Consumers should rely on the current Supplement Facts label for definitive ingredient and serving information and consult a qualified healthcare professional when appropriate.